Literature DB >> 2229793

Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length.

K A Boahene1, G J Klein, R Yee, A D Sharma, O Fujimura.   

Abstract

The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome. All patients received either procainamide (12 to 15 mg/kg body weight) or propafenone (1 to 2 mg/kg) during sustained (greater than 10 min) atrial fibrillation or after termination of nonsustained atrial fibrillation. Termination of atrial fibrillation was attributed to a drug if it occurred less than or equal to 15 min after infusion. Measurements included mean cycle length of fibrillatory electrograms (mean AA interval) as measured at the high right atrium and shortest RR interval between pre-excited cycles during atrial fibrillation. Atrial fibrillation terminated more frequently after procainamide administration (65%) than after propafenone (46%), although this difference was not significant. Procainamide prolonged the shortest pre-excited RR interval (228 +/- 41 to 339 +/- 23 ms, p = 0.0001) as did propafenone (215 +/- 40 to 415 +/- 198 ms, p = 0.0001) and the magnitude of increase was greater for propafenone (p = 0.048). Patients with sustained atrial fibrillation had shorter mean AA intervals than did their counterparts with nonsustained atrial fibrillation (123 +/- 25 versus 186 +/- 35 ms, p = 0.0001). Termination of sustained atrial fibrillation by either drug was accompanied by prolongation of the mean AA interval but not necessarily by the shortest pre-excited RR interval. Termination of atrial fibrillation was heralded by a 68% increase in the mean AA interval after procainamide administration compared with a 30% increase when the arrhythmia persisted. For propafenone the increases were 90% and 68%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229793     DOI: 10.1016/0735-1097(90)90384-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Exponential distribution of long heart beat intervals during atrial fibrillation and their relevance for white noise behaviour in power spectrum.

Authors:  Thomas Hennig; Philipp Maass; Junichiro Hayano; Stefan Heinrichs
Journal:  J Biol Phys       Date:  2006-12-15       Impact factor: 1.365

Review 2.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 3.  Guidelines for the use of propafenone in treating supraventricular arrhythmias.

Authors:  A G Kishore; A J Camm
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

4.  Frequency analysis of atrial fibrillation from the surface electrocardiogram.

Authors:  Daniela Husser; Martin Stridh; Leif Sornmo; S Bertil Olsson; Andreas Bollmann
Journal:  Indian Pacing Electrophysiol J       Date:  2004-07-01

5.  Efficacy of Nifekalant in Patients With Wolff-Parkinson-White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings.

Authors:  Jinzhu Hu; Jianhua Yu; Qi Chen; Jianxin Hu; Qianghui Huang; Zhen Xia; Zirong Xia; Zhenzhen Ju; Ping Yuan; Siyang Fan; Qinmei Xiong; Bo Zhu; Lin Huang; Chunjiao You; Huihui Bao; Yanqing Wu; Xiaoshu Cheng; Juxiang Li; Ali J Marian; Kui Hong
Journal:  J Am Heart Assoc       Date:  2019-06-25       Impact factor: 5.501

6.  Old stuff still trending: use of propafenone as a safety net until catheter ablation in a patient with documented pre-excited atrial fibrillation and Wolff-Parkinson-White syndrome - a classic case report.

Authors:  Dimitrios Karelas; John Papanikolaou; Charalampos Kossyvakis; Dimitrios Platogiannis
Journal:  Eur Heart J Case Rep       Date:  2021-11-30

7.  Low efficacy of cardioversion of persistent atrial fibrillation with the implantable cardioverter-defibrillator.

Authors:  I Limantoro; K Vernooy; B Weijs; R Pisters; L Debie; H J Crijns; Y Blaauw
Journal:  Neth Heart J       Date:  2013-12       Impact factor: 2.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.